49th week of 2008 patent applcation highlights part 39 |
Patent application number | Title | Published |
20080299012 | Adjustable laboratory rack - A laboratory rack assembly for supporting columns and receptacle tubes and other paraphernalia during laboratory procedures such as such as filtration, chromatography, plasma preparation, affinity purification, and so on, includes upper and lower support portions that are connected together for relative sliding movement. An upper rack module is connected to the upper support portion and is configured to receive at least one column. A lower rack module is connected to the lower support portion and is configured to receive at least one receptacle tube. At least one of the rack modules is removably connected to at least one of the support portions. An adjustment mechanism is operably associated with the upper and lower support portions for adjusting a position of one support portion with respect to the other support portion to thereby vary the distance between the upper and lower rack modules. | 2008-12-04 |
20080299013 | Chip-Holder for a Micro-Fluidic Chip - A chip-holder for holding a micro-fluidic chip has a fixer for detachably fixing the micro-fluidic chip in the chip-holder and at least one process control device configured to support control or monitoring of a chemical process in the micro-fluidic chip, wherein the chip-holder is configured such that the process control device and the micro-fluidic chip are directly and detachably coupled when the micro-fluidic chip is fixed in the chip-holder. Such a chip-holder brings along the advantage that the micro-fluidic chip can easily be removed and exchanged while the process control device can be reused. This reduces running costs of a chemical microreactor system drastically and allows for a very flexible usage of a chemical microreactor system. | 2008-12-04 |
20080299014 | AROMA DIFFUSER FOR VEHICLES - An aroma diffuser includes a housing, made up of a base, attached to a roof panel in a passenger compartment of a vehicle; and a cover coupled to the base. The cover has an inlet port, through which air in the passenger compartment is drawn, and an outlet port, through which the air is discharged. A motor and a fan are provided in the housing, the fan being operated by the motor. A filter is provided in the housing near an inlet of the fan. An aromatic-substance-containing case is provided in the housing near the fan. An aromatic substance is stored in the case, and the case is opened when the fan operates. A pollution sensor and a control unit are also provided in the housing. The control unit receives a signal from the pollution sensor, and controls the fan and the case. | 2008-12-04 |
20080299015 | Apparatus and method for top removal of granular material from a fluidized bed deposition reactor - Removal of the product from the top of the reactor enables a decreased disengaging height and provides a passive means of controlling the bed level despite deposition increasing the weight and height of the bed. The savings from reducing the disengaging height allow use of a taller fluidized bed in a shorter overall reactor length and thus provides increased production with reduced reactor cost. The separation of the gas inlet from the product outlet allows the gas inlet area to be cooler than the product outlet. The separation of the product grinding, caused by the inlet gas, from the product outlet reduces the loss of seed in the product and produces a more uniform product. Removing the hot product and the hot gas at the same place allows energy recovery from both in a single step. | 2008-12-04 |
20080299016 | SYSTEM AND METHOD FOR SELECTIVE CATALYTIC REDUCTION OF NITROGEN OXIDES IN COMBUSTION EXHAUST GASES - A multi-stage selective catalytic reduction (SCR) unit ( | 2008-12-04 |
20080299017 | Photoreactor - The photoreactor comprises a tube bundle ( | 2008-12-04 |
20080299018 | BIOMASS TO LIQUIDS PROCESS - The present invention relates to a biorefinery system for conserving resources, whereby the system has a refining unit, at least one bio-oil unit, and a host site. | 2008-12-04 |
20080299019 | System and process for upgrading heavy hydrocarbons - A system and process for upgrading hydrocarbons such as heavy oils includes high temperature plasma reactor apparatus, in one or more vessels, into which the oils are introduced along with water, such as steam, to produce lighter hydrocarbon fractions, along with carbon monoxide and hydrogen, that flows to an additional stage where more hydrocarbons and water are introduced for further fractionating reactions facilitated by reaction of carbon monoxide and water to produce carbon dioxide and nascent, or prompt, free radicals of hydrogen. Heavy hydrocarbons upgraded can include heavy oils in the form of tar sands, oil shale, and oil residuals. The vessel or vessels can each contain a carbonaceous bed facilitating the described reactions and example embodiments include one vessel with the reactions performed in a single bed and, also, two vessels with the reactions performed in a carbonaceous bed portion in each vessel. | 2008-12-04 |
20080299020 | Apparatus for manufacturing group III nitride semiconductor - An apparatus for manufacturing a Group III nitride semiconductor is composed of a pressure vessel, a reaction vessel disposed within the pressure vessel, a heating device disposed within the pressure vessel so as to heat the reaction vessel, and a glove box filled with argon gas. The pressure vessel and the glove box are connected to each other via a gate valve. By virtue of this configuration, a large-sized reusable reaction vessel can be disposed within the pressure vessel without causing oxidation of Na. | 2008-12-04 |
20080299021 | SYSTEM FOR THE PRODUCTION OF SYNTHETIC FUELS - A system and method for producing synthetic fuels are disclosed in which a slurry comprised of a particulate solid portion dispersed in a carrier liquid portion is provided. The solid portion comprises (i) a feedstock of carbon-containing polymeric materials that are substantially free of each of halogen, sulfur and nitrogen atoms, and contain about 5 to about 25 percent by weight water, and (ii) a catalytic amount of metal particles. The carrier liquid portion is a hydrocarbon/oxyhydrocarbon composition. The feedstock constitutes about 10 to about 60 weight percent of the slurry. The slurry is heated anaerobically to provide an elevated temperature of about 250° to about 455° C. and a pressure of about 20 to about 50 atmospheres that are maintained for a time period sufficient to provide a combustible liquid fuel at least 80 percent of which contains about 6 to about 21 carbon atoms per molecule. | 2008-12-04 |
20080299022 | PROCESS FOR PRODUCING LIQUID AND, OPTIONALLY, GASEOUS PRODUCTS FROM GASEOUS REACTANTS - An installation for producing liquid and, optionally, gaseous products from gaseous reactants. The installation has a reactor vessel having a vertically extending slurry bed zone; a first gas inlet in the vessel at a low level within the slurry bed zone for introducing gaseous reactants; a second gas inlet in the vessel at a level within the slurry bed zone which is above the first gas inlet for introducing recycled gas, the second gas inlet in the vessel being above the lower 20% of the vertical height of the slurry bed zone; a gas outlet in the vessel above the slurry bed zone, for withdrawing gas from a head space above the slurry bed zone and a liquid outlet in the vessel within the slurry bed zone, for withdrawing liquid product from the vessel. | 2008-12-04 |
20080299023 | CONSOLIDATED VACUUM SUBLIMATION MODULE - A consolidated vacuum sublimation module (VSM) can comprise an upper body portion, a middle body portion, a lower body portion, a bushing, and a seal. A vapor director cartridge can be loaded with a crude material and manually inserted into a cartridge-holding member of the lower body portion. Assembly of the middle and upper body portions form a structural unit that can compressively and sealably connect to the lower body portion. During sublimation, heat is effectively transferred to the lower body portion that contains the crude material. A substantial fraction of the middle body portion is conically tapered about a central longitudinal axis to promote desublimation. The middle body portion is a unitary structure that consolidates valving, cooling, and desublimation functions. Following completion of an operational cycle, the vacuum sublimation module is inspected for sublimate presence, then valve-isolated, suitably cooled, detached, opened to a preferred gaseous atmosphere, disassembled, and manipulated for solids recovery. | 2008-12-04 |
20080299024 | Method For Industrial Manufacture Of Pure MgCo3 From An Olivine Containing Species Of Rock - Method for industrial manufacture of pure MgCO | 2008-12-04 |
20080299025 | Oxidizing Reactor for Molybdenum Sulphide and its Associated Process - A reactor for molybdenum sulphide (MoS2), wherein MoS2 is ionized by an electric field generated by a first set of magnetrons at a frequency in the range of 2500-3500 MHz and heated by a variable magnetic field of 2500 Hz produced by a winding coil, resulting in the exclusive evaporation of molybdenite. MoS2 in gas state is then stimulated by a second set of magnetrons and, with the injection of air, oxidized until trioxide is obtained. Hot gases essentially containing molybdenum trioxide, sulphur dioxide, and nitrogen are conducted from a first body towards a second body though a first duct. Cold air is added to the second body through a second duct to cool the gas, and crystals formed by liquefaction settle and are removed through a lower duct while gases at a temperature of 600° C. are conducted through a higher duct. | 2008-12-04 |
20080299026 | Process for the Removal in Continuous of Hydrogen Sulfide From Gaseous Streams - Process for the removal in continuous of hydrogen sulfide from gaseous streams containing it, comprising: a) putting a gas containing H | 2008-12-04 |
20080299027 | SCINTILLATOR SINGLE CRYSTAL, HEAT TREATMENT METHOD FOR PRODUCTION OF SCINTILLATOR SINGLE CRYSTAL, AND METHOD FOR PRODUCTION OF SCINTILLATOR SINGLE CRYSTAL - The scintillator single crystal of the invention comprises a cerium-activated orthosilicate compound represented by the following general formula (1). The scintillator single crystal of the invention exhibits improved scintillation properties by reduced segregation between elements in the crystal ingot. | 2008-12-04 |
20080299028 | CATALYST AND PROCESS FOR THE CONVERSION OF NITROUS OXIDE - A catalyst composition and a process for using it to decompose nitrous oxide into nitrogen and oxygen are disclosed. The catalyst composition has surface area of about 1 to about 200 m | 2008-12-04 |
20080299029 | Gas-Phase Process for Growing Carbon Nanotubes Utilizing Sequential Multiple Catalyst Injection - This invention relates generally to a method and apparatus for making carbon nanotubes from a flowing gaseous carbon-containing feedstock, such as CO, at superatmospheric pressure and at temperatures between about 500° C. and about 2000° C. utilizing a reactor wherein the flowing carbon-containing feedstock sequentially passes multiple points of catalyst injection, where the catalyst is provided by the decomposition of one or more catalyst precursor species, such as Fe(CO) | 2008-12-04 |
20080299030 | HIGHLY ACCESSIBLE, NANOTUBE ELECTRODES FOR LARGE SURFACE AREA CONTACT APPLICATIONS - An highly porous electrically conducting film that includes a plurality of carbon nanotubes, nanowires or a combination of both. The highly porous electrically conducting film exhibits an electrical resistivity of less than 0.1 O·cm at 25 C and a density of between 0.05 and 0.70 g/cm | 2008-12-04 |
20080299031 | Method for making a carbon nanotube film - The present invention relates to a method for making a carbon nanotube film. The method includes the steps of: (a) forming an array of carbon nanotubes on a substrate; and (b) press the array of carbon nanotubes using a compressing apparatus, thereby forming a carbon nanotube film. | 2008-12-04 |
20080299032 | Process For Producing Supported Ruthenium and Process For Producing Chlorine - The present invention provides a process for producing supported ruthenium, which comprises recovering a ruthenium compound from supported ruthenium used as a catalyst in production of chlorine by oxidation of hydrogen chloride with oxygen, and supporting the ruthenium compound on a carrier; and a process for producing chlorine, which comprises producing a supported ruthenium catalyst by the process mentioned above and oxidizing hydrogen chloride with oxygen in the presence of the supported ruthenium. | 2008-12-04 |
20080299033 | Inorganic Metal Chalcogen Cluster Precursors and Methods for Forming Colloidal Metal Chalcogenide Nanoparticles Using the Same - Methods for forming colloidal metal chalcogenide nanoparticles generally include terming soluble inorganic metal chalcogen cluster precursors, which are then mixed with a surfactant and heated to form the colloidal metal chalcogenide nanoparticles. The soluble inorganic metal chalcogen cluster precursors are generally formed using a hydrazine-based solvent. The methods can be used with main group and transition metals. | 2008-12-04 |
20080299034 | PROCESS FOR PREPARING HYDROGEN PEROXIDE - The present invention relates to a process for preparing hydrogen peroxide by reacting hydrogen and oxygen in the presence of a solvent and of a catalyst, wherein the catalyst comprises at least one noble or semi-noble metal supported on an inorganic material functionalized with acid groups. The invention also refers to the catalyst used in this process. | 2008-12-04 |
20080299035 | Method for recycling used sputtering target - A method for recycling a used sputtering target is provided, including the steps of: (1) cleaning, (2) pulverization, (3) dissolution, (4) filtering, (5) peptization, (6) neutralization and precipitation, (7) rinsing and filtering, (8) drying, and (9) calcination; through the steps above, which can then be recycling used sputtering target to recover the constituent components of the ITO targets. | 2008-12-04 |
20080299036 | Methods for Production of Titanium Oxide Particles, and Particles and Preparations Produced Thereby - The invention provides a method for the formation of small-size titanium oxide particles, comprising the steps of a) preparing a starting aqueous solution comprising at least one of titanic ions and complexes thereof, at a concentration of at least 0.1% w/w titanium; b) maintaining the solution at a temperature lower than 70° C. for a retention time in which hydrolysis takes place, the extent of the hydrolysis being sufficient to produce 0.1 mmol protons per mmol of titanium present in solution, wherein the time does not exceed 14 days, to form a system containing a retained solution; and c) adjusting the conditions in the system by at least one of the steps of: i) heating the retained solution to elevate the temperature thereof by at least 1° C.; ii) changing the pH of the retained solution by at least 0.1 units; and iii) diluting the retained solution by at least 20% whereby there are formed particles, wherein the majority of the particles formed are between about 2 nm and about 500 nm in size. | 2008-12-04 |
20080299037 | Method for Purifying Germanium Hydrides - An improved method for purifying gaseous mixtures of germanium hydrides and hydrogen is disclosed. In one aspect, the crude gas is contacted with a cold caustic solution to reduce levels of carbon dioxide and water. The partially purified gas is chilled in direct-contact with a hydrogen refrigerant to induce homogenous condensation of water impurity. Liquid and ice particles formed by lower temperatures are removed across an aerosol phase separating medium to produce a cooled and partially purified gas mixture which is further dried and de-carbonated across a zeolitic molecular sieve adsorbent to achieve very low concentrations of moisture and carbon dioxide in the bulk gas. In one aspect, the purified gas mixture obtained is partially liquefied, phase-separated and distilled to obtain germanium hydride, digermanium hexahydride and hydrogen gas as products. A portion of the hydrogen product can be compressed, chilled and re-used as a direct-contact refrigerant in the purification process. | 2008-12-04 |
20080299038 | Luminescent Metal Complexes for Monitoring Renal Function - Some embodiments of the present invention may be said to be directed to metal complexes of Formula I, wherein at least one of X | 2008-12-04 |
20080299039 | Aprotinin Polypeptides for Transporting a Compound Across the Blood-Brain Barrier - The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides derived from aprotinin and from aprotinin analogs as well as conjugates and pharmaceutical compositions comprising these polypeptides or conjugates. The present invention also relates to the use of these polypeptide for transporting a compound or drug across the blood-brain barrier of a mammal and in the treatment and diagnosis of neurological diseases. | 2008-12-04 |
20080299040 | SOMATOSTATIN RECEPTOR 2 ANTAGONISTS - The invention is directed to somatostatin analogs which are receptor antagonists of the somatostatin receptor, including receptor-selective antagonists, especially sst2-selective antagonists. Related compounds and compositions are included, including antagonists complexed with or conjugated to radioactive nuclides. The antagonists of the invention are useful in diagnosing and treating neoplastic and non-neoplastic mammalian diseases; such methods, and kits, are encompassed. | 2008-12-04 |
20080299041 | HETEROCYCLIC INDENE DERIVATIVES AND THEIR RADIOISOTOPE LABELED COMPOUNDS FOR IMAGING BETA-AMYLOID DEPOSITION - The invention is directed to heterocyclic indene derivatives useful for β-amyloid plaque imaging, their radiolabeled compounds and their preparation methods. The compounds of the invention are easily labeled with radioisotopes and have high affinities to β-amyloid depositions, thus they facilitate diagnosis of Alzheimer's disease by imaging the distribution of β-amyloid depositions. | 2008-12-04 |
20080299042 | Membrane Associated Molecules - The present invention is directed to novel methods of treating, identifying or diagnosing a hyperproliferative disorder in a patient in need thereof. The methods of the invention include administering to a patient a composition comprising a binding molecule which binds to a cell surface expressed glycoprotein expressed predominantly in tumor or tumor-associated cells. In particular, the therapeutic and diagnostic methods of the present invention include the use of a binding molecule, for example an antibody or immunospecific fragment thereof, which specifically binds to a membrane associated molecule, variant polypeptide or fragment thereof. The present invention is based, at least in part, on the discovery of membrane associated proteins, i.e., nucleic acid molecules which encode membrane proteins and the use of these molecules to generate custom arrays to screen for markers associated with various diseases and disorders, e.g., cancer, e.g., lung, colon, pancreatic and ovarian cancer and autoimmune diseases or disorders. The invention further relates to various methods, reagents and kits for diagnosing, staging, prognosing, monitoring and treating hyperproliferative diseases or disorders such as cancer, e.g., lung, colon, pancreatic and ovarian cancer and autoimmune diseases or disorders. | 2008-12-04 |
20080299043 | HIGHER FATTY ACID TRIESTER COMPOUND HAVING DIETHYLENETRIAMINE-TYPE METAL CHELATE STRUCTURE - A compound having superior solubility and suitable for a liposome contrast medium selective for a lesion such as vascular diseases is provided which is represented by the following general formula (I) | 2008-12-04 |
20080299044 | Saccharide Fluorescent Substrates, Preparation Method and Uses Thereof - The invention concerns saccharide type fluorescent enzymatic substrates comprising on the same saccharide unit a fluorophor F1 and an inhibitor of the fluorescence of F1, and their use for preparing a diagnostic reagent for in vivo functional imaging, as well as a diagnostic reagent containing at least such an enzymatic substrate. | 2008-12-04 |
20080299045 | Composition for Prevention, Treatment, and Diagnosis of Chronic Obstructive Pulmonary Disease (Copd) - The present invention provides a pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease (COPD) comprising cytokeratin 18 protein as an active ingredient. The present invention also provides a diagnostic composition and a diagnostic kit for diagnosing COPD comprising cytokeratin 18 protein. The present invention further provides a composition for screening a therapeutic agent for COPD, comprising one or more of cytokeratin 18 protein or autoantibodies to cytokeratin 18 obtained from patients with COPD and a method for screening a therapeutic agent for COPD using this composition. The present invention still further provides methods for diagnosing, preventing or treating COPD using cytokeratin 18 protein. | 2008-12-04 |
20080299046 | METHODS FOR CONTROLLING SURFACE FUNCTIONALITY OF METAL OXIDE NANOPARTICLES, METAL OXIDE NANOPARTICLES HAVING CONTROLLED FUNCTIONALITY, AND USES THEREOF - Methods for controlling surface functionality of metal oxide nanoparticles, nanoparticles having controlled surface functionality, and uses thereof are described herein. Methods for controlling the surface functionality of a metal oxide nanoparticle are can include attaching a ligand to a metal oxide nanoparticle, where the ligand can include a functional portion that is capable of forming an irreversible bond with an object at a site that is complementary to the functional portion without reacting with other reactive sites that may be present. Moreover, metal oxide nanoparticles having versatile ligands can include an anchoring portion that binds to the surface of the metal oxide nanoparticle and a functional portion that is capable of forming an irreversible bond with an object at a site that is complementary to the functional portion without reacting with other reactive sites that may be present. Uses thereof can include cancer detection, electronics, cosmetics, cellular delivery carriers, magnetic storage media, drug delivery carriers, nanocomposite formation for improved mechanical properties, and the like. | 2008-12-04 |
20080299047 | Method for preparation of water-soluble and dispersed iron oxide nanoparticles and application thereof - The present invention relates to a process for preparing water-soluble and dispersed iron oxide (Fe | 2008-12-04 |
20080299048 | MIXED DRUG AEROSOL COMPOSITIONS - The present invention pertains to aerosols which comprise a first compound which is physiologically active and a second compound which is different from the first compound. Such aerosols may be produced “on demand” and can be used to control drug release, to improve vaporizability, or to reduce, modify or eliminate undesirable taste associated with a drug aerosol. The present invention also pertains to methods for producing such aerosols. | 2008-12-04 |
20080299049 | Inhalation nebulizer - The aerosol generator of an inhalation therapy device according to a preferred embodiment of the invention continuously produces an aerosol at a generation rate of about 0.2 ml/min to about 1.5 ml/min, preferably 0.4 ml/min to about 1.2 ml/min and the mixing chamber has a volume of about 60 ml to about 150 ml, preferably about 80 ml to about 120 ml, and even more preferably about 90 to about 110 ml. While the patient inhales through the inhalation therapy device, the generated aerosol is inhaled by the patient. While the patient exhales into the inhalation therapy device, the generated aerosol is collected in the mixing chamber. Due to the specific size of the mixing chamber, the continuously generated aerosol can accumulate therein without losses even when the exhalation phase is longer than the inhalation phase like in the case of emphysema. | 2008-12-04 |
20080299050 | TOPICAL THERAPIES FOR ORAL MUCOSITIS AND OTHER CONDITIONS - A method for treating oral mucositis in a subject comprises topically administering to an oral mucosal surface of the subject phenyloin or a pharmaceutically acceptable salt thereof in an amount effective to inhibit mucosal degeneration or promote mucosal regeneration, and optionally an analgesic agent in an amount effective, in combination with the phenyloin or salt thereof, to reduce pain associated with the oral mucositis. The phenyloin or salt thereof and optionally the analgesic agent can be administered in a pharmaceutical composition comprising an excipient vehicle suitable for intraoral administration, said composition being bioadhesive to an oral mucosal surface, for example having at least one non-lipoidal internal phase and at least one lipoidal external phase that is bioadhesive to said surface. | 2008-12-04 |
20080299051 | Pharmaceutical composition for the oral hygiene, the treatment of the periodontal illnesses and the halitosis - The invention is a pharmaceutical composition for the oral hygiene for the treatment of the periodontal illnesses and the Halitosis. It consists of a mixture 0.01 a 5 g of Hydrogen Peroxide; 0.001 a 0.5 g de Eugenol: 0.001 a 0.5 g de Permonochlorophenol; 0.001 a 0.3 g of Camphor; 10 a 40 g de Maltitol; 0.01 a 0.1 g of coloring matter; 0.1 a 1 g of appetizing substance and enough quantity of demineralized water to complete 100 g of oral pharmaceutical preparation. | 2008-12-04 |
20080299052 | Formulation to Prevent Plaque Formation - A composition for preventing plaque formation comprises; 98.267 kg deionised water; 0.2 kg delmopinol; 0.01 kg sodium saccharide; 0.02 kg herb flavour COD 76634-34; 1.5 kg 99.5% ethanol; and 0.003 kg sodium hydroxide. | 2008-12-04 |
20080299053 | ENHANCED DELIVERY OF CERTAIN FRAGRANCE COMPONENTS FROM PERSONAL CARE COMPOSITIONS - A personal care composition is provided having a fragrance which incorporates limonene, gamma terpinene, ethylene brassylate or combinations thereof in conjunction with a quaternary ammonium salt. The salt has a structure AB, wherein A is a cationic charge component, B is an anionic charge component, and A has one quaternized nitrogen atom, at least two hydroxyl groups and a molecular weight no higher than about 250. The quaternary ammonium salt functions as a scent boosting agent to enhance volatilization of the fragrance components when the personal care composition is first applied to skin or hair of the human body. | 2008-12-04 |
20080299054 | PERSONAL CARE COMPOSITIONS WITH ENHANCED FRAGRANCE DELIVERY - A personal care product is provided which includes a fragrance, a substituted urea and a quaternary ammonium salt. The substituted urea and quaternary ammonium salt operate together as a scent boosting system to enhance volatilization of fragrance components upon the personal care composition being first applied to human skin or hair. | 2008-12-04 |
20080299055 | Monomer 5, 6-Diphenyl-1.2.4-Traizinic Derivatives and the Use Thereof - The invention relates to the use of 5,6-diphenyl-1,2,4-triazinic compounds of general formula (I), wherein cycle penetrating bonds display an ortho, meta or para indifferent substitution position, identical or different R | 2008-12-04 |
20080299056 | Passivated nano-titanium dioxide particles and methods of making the same - The invention is directed to a method for reducing the chemical activity and photo activity of titanium dioxide nanoparticles comprising adding a densifying agent, such as citric acid, to an aqueous slurry of the titanium dioxide nanoparticles; treating the aqueous slurry with a source of silica, such as a solution of sodium silicate, to form silica treated titanium dioxide nanoparticles; treating the silica treated titanium dioxide nanoparticles with a source of alumina, such as a solution of sodium aluminate, to form silica and alumina treated titanium dioxide nanoparticles. The titanium dioxide nanoparticles described herein are useful in cosmetic, coating and polymer compositions. | 2008-12-04 |
20080299057 | Method and compositions for dispersing particulate solids in oil - This invention relates to a method for preparing dispersions of solid particles, especially pigments, metal oxides and mineral fillers in organic media, to dispersing compositions used in this method and to dispersions containing these dispersion compositions. The dispersing compositions include an oil soluble surfactant selected from the group consisting of phospholipids, alkyl acids, nonionic surfactants having an HLB less than 10, and mixtures thereof; either an anhydride based polymer selected from the group consisting of polyalkene succinic anhydrides; maleinized polyisoprene; maleinized polybutadiene; maleinized copolymers of isoprene and butadiene; copolymers of styrene and maleic anhydride; derivatives formed by reaction of the anhydride group of the anhydride based polymer with one or more of water, amines, alcohols, and polyols; and mixtures thereof; or a mixture of the said anhydride based polymer with polyhydroxystearic acid; and optionally a liquid oil carrier. | 2008-12-04 |
20080299058 | Multi-formulation cosmetic compositions - The present invention relates to a cosmetic composition a) from about 10% to about 90% of water-in-oil emulsion as a first formulation which comprises i) from about 0.1% to about 15% of an emulsifying crosslinked siloxane elastomer; ii) from about 1% to about 40% of a solvent for the emulsifying crosslinked siloxane elastomers; and iii) from about 40% to about 99% of an aqueous phase; and b) from about 10% to about 90% of a second formulation, wherein the first and second formulations are of different formulation, and wherein when shear stress is applied to the composition during spreading on skin, at least a part of the aqueous phase is released from the first formulation. | 2008-12-04 |
20080299059 | COSMETIC COMPOSITIONS CONTAINING FUNCTIONALIZED METAL-OXIDE LAYERED PIGMENTS AND METHODS OF USE - The disclosure relates to cosmetic compositions containing functionalized metal-oxides layered pigments. The disclosure also relates to the use of the functionalized metal-oxide layered pigments in cosmetics such as hair, eyes, lips, skin and nail compositions. The metal-oxide layered pigments are functionalized with ligands which provide improved properties to the pigments in the cosmetics. | 2008-12-04 |
20080299060 | Pharmaceutical Composition for the Treatment of Nail Diseases - A method for topically and systemically delivering a pharmaceutical composition to a human nail is disclosed, said method comprising the application of a pharmaceutical composition to the nail, covering the nail and the pharmaceutical composition with a protective layer, and a dissolvent to remove the protective layer and the pharmaceutical composition after a certain time of action and before reapplication. Preferably the method is combined with a laser pretreatment of the nail to drill arrays of partial orifices to enhance the permeability of drugs through the nail plate. | 2008-12-04 |
20080299061 | Skin Whitening Cosmetic Composition, Pack Containing the Same, and Preparation Method Thereof - A skin whitening cosmetic composition having excellent whitening effects without causing any side effects, which includes a carbonized pine cone, as well as a pack containing the same. The skin whitening cosmetic composition includes natural substances, unlike prior commercially available products, and has excellent whitening effects without causing any side effect since it is safe to the skin. When the whitening cosmetic composition is used as it is or as a pack together with a substrate, such as a nonwoven fabric, it will provide a functional pack that can impart whitening effects in addition to effects, such as skin moisturization and skin firming. | 2008-12-04 |
20080299062 | Use of Oxocarboxylic Acids-Containing Combinations for Deodorization - Described is the use of a combination of an oxocarboxylic acid with metal ions, organic bases or polymers substantive for keratin material for combating, suppressing or eliminating odors of the hair of skin. Preferred oxocarboxylic acids are those of general formula R—C(═O)—A—CO | 2008-12-04 |
20080299063 | HAIR COSMETIC COMPOSITION - Provided is a hair cosmetic composition containing (A) an amidoamine (1) or an etheramine (2), or a salt thereof, (B) a branched fatty acid (3) or a salt thereof, (C) a silicone, and water: | 2008-12-04 |
20080299064 | COMPOSITIONS AND METHOD FOR MANAGEMENT OF HEAD LICE - A composition for the management of head lice includes a hair treatment base which is at least partially hair conditioner and a coloring agent in a concentration sufficient to colorize lice nits covered with the composition. The composition does not include a pediculicide selected from the group consisting of organochlorines, organophosphates, carbamates, pyrethrins, pyrethroids and neurotoxins. A method includes applying the composition to the wetted hair of a human with a lice infestation, rinsing the composition from the hair after the nits are colorized, and removing nits from the hair by visual inspection. | 2008-12-04 |
20080299065 | COMPOSITION CONTAINING SULFONIC ACID AND/OR SULFURIC ACID COMPOUND - Composition containing an aqueous phase and an emulsifying system comprising a sulfonic acid compound or a salt of the compound, or a sulfuric acid compound or a salt thereof, and mixtures thereof. | 2008-12-04 |
20080299066 | ENERGY-ACTIVATED COMPOSITIONS FOR CONTROLLED SUSTAINED RELEASE OF A GAS - A composition for energy-controlled generation and release of at least one gas, which includes an energy-activated catalyst capable of being activated by electromagnetic energy, and a solid or a liquid containing anions capable of being oxidized by the activated catalyst or reacted with species generated during activation of the catalyst to generate at least one gas. The composition, when exposed to electromagnetic energy, is capable of generating and releasing the gas after activation of the catalyst and oxidation or reaction of the anions. | 2008-12-04 |
20080299067 | Functionalised Siloxanes for Scar Tissue Treatment - A novel composition for use in treating a wound, burn or other skin condition comprises one or more compounds of formula (I), wherein: m = 0-6, n = 6-100, Q, R and R′ may be independently selected from, C1-5 alkyl, OU, UOCH2CH3, CH2CH3, UOCH3, OH, O(CH2)y(OU)yCH3, (OCH2CH2)yOU, (OCH2CH2)yOH, UOH, UOU′, UCO2U′, CO2U, UCO2COU, CO2H, UCO2H, COX, UCOX, UCO2 R′, CO2COU, Aryl, ArylU, ArylUU, ArylUU′U″, NH2, UNH2, NHU, NUU′, NO2, UNO2, UCONH2, CONH2, UCONHU′, CONHU, UCONU′U″, CONU′U″, halogen, PO4H3, PO4H3-z, PO4H3-zU (z = 0, 1, 2 or 3), PU3, P U′U″U′″SH, SO2 and SO3H; wherein U, U′, U″ and U′″ may be independently selected from any alkyl, alkenyl or alkynyl group where the number of carbon atoms is between 1 and 31; wherein X=halogen; wherein y=1-100; provided that Q, R and R′ can not all be C1 alkyl; and wherein the compound of formula (I) is present in an amount of at least 1% of the composition. | 2008-12-04 |
20080299068 | Skin Preparation For External Use - The present invention provides an external composition for skin that has excellent effects in improving elasticity and alleviating wrinkles while moisturizing the skin, has good spreadability on the skin, and has no stickiness. The external composition for skin of the present invention is characterized by comprising: (A) an acrylic polymer comprising the following monomers (a1), (a2), and (a3) as constituent monomers: (a1) acrylic acid or methacrylic acid; (a2) an alkyl acrylate or alkyl methacrylate; and (a3) an ester between acrylic acid or methacrylic acid and polyoxyethylene alkyl ether; and (B) a cross-linked polyamino acid or its salt. In the external composition for skin of the present invention, it is preferable that (A) is 0.01 to 10.0 weight % as a polymer, and (B) is 0.0001 to 5.0 weight % as a polymer. | 2008-12-04 |
20080299069 | Polymer Derivatives Comprising an Acetal or Ketal Branching Point - The invention provides a polymer comprising (i) a first water-soluble polymer segment that is covalently attached, either directly or through one or more atoms, to a first oxygen atom that is covalently attached to a linking carbon atom; (ii) a second water-soluble polymer segment is covalently attached, either directly or through one or more atoms, to a second oxygen atom that is covalently attached to the linking carbon atom; and (iii) a reactive group that is covalently attached, either directly or through one or more atoms, to the linking carbon atom. The invention also provides, among other things, methods for preparing polymers, conjugates, pharmaceutical compositions and the like. | 2008-12-04 |
20080299070 | Antiviral Compounds - The present invention relates to novel antiviral compounds which are covalently attached to solid, macro surfaces. In another embodiment, the invention relates to novel antiviral compositions including a polymeric material and, embedded therein, an antiviral compound. In other embodiments, the invention relates to making a surface antiviral and making a polymeric material antiviral. | 2008-12-04 |
20080299071 | Stable aqueous solutions of granulocyte macrophage colony-stimulating factor - The invention provides formulations of GM-CSF to which a chelating agent has been provided to stabilize the GM-CSF against N-terminal degradation. | 2008-12-04 |
20080299072 | Chemokine Antagonists - New CC-chemokine antagonists are provided. Compounds prepared in accordance with the present invention can be used as anti-inflammatory and immunomodulatory compounds and in the treatment or prevention of CC-chemokine-related diseases. | 2008-12-04 |
20080299073 | Method For Treatment Or Prophylaxis Of An Infection Using Either An Antibody Which Binds To IL-9 Or An Agent Which Stimulates Production Of Autoantibodies To Interleukin-9 - The invention relates to methods for the treatment and/or prophylaxis of infections that produce an imbalance of Th1 and Th2 CD4 cells such as Leishmaniasis, via the administration of an antibody to IL-9 or an agent that stimulates production of anti-IL-9 antibodies sufficient to neutralize native IL-9 in a subject. | 2008-12-04 |
20080299074 | A-BETA IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME - The present invention is directed to methods of producing conjugates of Aβ peptide immunogens with protein/polypeptide carrier molecules, which are useful as immunogens, wherein peptide immunogens are conjugated to protein carriers via activated functional groups on amino acid residues of the carrier or of the optionally attached linker molecule, and wherein any unconjugated reactive functional groups on amino acid residues are inactivated via capping, thus retaining the immunological functionality of the carrier molecule, but reducing the propensity for undesirable reactions that could render the conjugate less safe or effective. Furthermore, the invention also relates to such immunogenic products and immunogenic compositions containing such immunogenic products made by such methods. | 2008-12-04 |
20080299075 | HEPATITIS C VIRUS INHIBITORS - The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. | 2008-12-04 |
20080299076 | Compunds and compositions that cause non-apoptotic cell death and uses thereof - The present invention relates to erastin analogs, particularly compounds of formulae I and II, including compounds 1-20, 22-24, 34, and 40. The invention also relates to pharmaceutical compositions containing such analogs and to methods of treating conditions in a mammal with such analogs and pharmaceutical compositions. | 2008-12-04 |
20080299077 | ISOLATION AND GROWTH OF STEM CELLS FROM HEMANGIOMAS - The present invention describes stem cells and progenitor cells derived from hemangiomas, including testing of angiogenic inhibitors using these cells. The invention as described is useful in providing a process to culture and propagate hemangioma stem cells and generate xenograft models to develop treatments for infantile hemangiomas and other types of vascular lesions. | 2008-12-04 |
20080299078 | TUMOR ASSOCIATED AMINO ACIDS AND USES THEREFOR - The invention describes SAGE (sdph3.10) and sdp3.5 tumor associated nucleic acids, including fragments and biologically functional variants thereof. Also included are polypeptides and fragments thereof encoded by such nucleic acid molecules, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a sdph3.10 and/or sdp3.5 gene product. | 2008-12-04 |
20080299079 | Absorption Enhancers for Drug Administration - A composition including a surfactant and at least one alkyl glycoside and/or saccharide alkyl ester and a drug. The surfactant composition(s) when admixed with a drug is non-toxic and non-irritating, while stabilizing and increasing the bioavailability of the drug. The invention also provides compositions that enhance absorption of drugs via the oral, ocular, nasal, nasolacrimal, inhalation or pulmonary, oral cavity (sublingual or Buccal cell) or CSF delivery route of a patient, including but not limited to insulin, glucagon and exendin-4. | 2008-12-04 |
20080299080 | Thiophene analogues for the treatment or prevention of flavivirus infections - Compounds represented by formula I: | 2008-12-04 |
20080299081 | Polynucleotides and Polypeptides of the IFNalpha-21 Gene - Polynucleotides and polypeptides derived from the nucleotide sequence of the IFNα-21 gene comprising SNPs, and their therapeutic uses. | 2008-12-04 |
20080299082 | Novel recombinant T4 phage particle containing HIV, H. pylori or cancer antigens and uses thereof - The invention is directed to a novel recombinant T4 phage particle expressing a HOC and/or SOC | 2008-12-04 |
20080299083 | Adenoviral vectors having a protein IX deletion - This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. | 2008-12-04 |
20080299084 | BACTERIALLY DERIVED INTACT MINICELLS THAT ENCOMPASS PLASMA FREE FUNCTIONAL NUCLEIC ACID FOR IN VIVO DELIVERY TO MAMMALIAN CELLS - Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation. | 2008-12-04 |
20080299085 | High-throughput assay for virus entry and drug screening - The present invention provides a rapid virus entry/binding detection assay. An enzyme such as luciferase was incorporated at the C-terminal end of viral envelope proteins of the HIV Nef protein that would specifically associate with cell membranes to deliver the enzyme into viral particles upon viral assembly. Virus entry/binding can then be assayed by determining the enzymatic activities in infected cells. The assay allows high-throughput non-radioactive detection of virus entry within 30 minutes after virus-cell contact. This assay provides high signal to noise ratio and is useful for screening compounds that affect virus-cell binding and entry. The design also permits packaging of potential therapeutic proteins into functional virus particles and delivering them to specific cellular targets. | 2008-12-04 |
20080299086 | Cultured muscle cells with high metabolic activity and method for production of the cultured muscle cells - The object of the present invention is to provide a method of preparing excellent cultured muscle cells having high metabolic capacity and insulin responsiveness, and further provide a method for the measurement of sensitive metabolic capacity using the cells. Moreover, its purpose is to provide a culture system/culture apparatus that can smoothly translocate such highly advanced cultured muscle cells intact to activity evaluation systems of a number of drugs. Moreover, the object of the present invention is to provide cultured muscle cells that are very suitable for measurement of the membrane-translocation activity of GLUT4 in an extraneous stimulus-dependent manner such as insulin, etc., and to provide a method for the measurement of the membrane-translocation activity of GLUT4 using the cells. The present invention is a method of preparing myotube cells, comprising a step (1) of culturing myoblast cells, a step (2) of differentiation-inducing the myotube cells into the myoblast cells in a culture medium with a high content of amino acids, and a step (3) of applying an electric pulse to the differentiation-induced myotube cells, and a method for the measurement of insulin-dependent sugar uptake using the myotube cells prepared by said method, and relates to the method for the measurement, comprising applying insulin stimulation by culturing the cells in a culture medium containing insulin, culturing the cells in the culture medium further supplemented with sugar, and measuring the sugar uptake. Furthermore, the present invention relates to a differentiation-type culture myotube cell constitutively expressing a recombinant GLUT4 having a labeled substance at its extra-cellular site, which is prepared by co-culturing wild-type myoblast cells and recombinant myoblast cells constitutively expressing said recombinant GLUT4, and a method for the measurement of membrane-translocation activity of the recombinant GLUT4 using the cells, and particularly a method for the measurement of insulin-dependent sugar uptake activity. | 2008-12-04 |
20080299087 | Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition - Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases. | 2008-12-04 |
20080299088 | Uses of Notch Receptors, Notch Ligands, and Notch Modulators in Methods Related to Metabolic Diseases - Disclosed are methods for identifying and isolating a precursor cell. Also, disclosed are methods of increasing insulin synthesis from a pancreatic β-cell. Further, disclosed are methods of improving pancreatic β-cell function. Still further, disclosed are methods of preventing or delaying the onset of a metabolic disease, methods of treating or preventing a metabolic disease in a subject, and to compositions for treating or preventing a metabolic disease in a subject in need of such treatment or prevention. | 2008-12-04 |
20080299089 | ENDOGENEOUS REPAIR FACTOR PRODUCTION PROMOTERS - It relates to an endogenous repair factor production accelerator which comprises one or at least two selected from prostaglandin (PG) 12 agonist, EP2 agonist and EP4 agonist. Since prostaglandin (PG) 12 agonist, EP2 agonist or EP4 agonist has various endogenous repair factor production accelerating action, angiogenesis acceleration action and stem cell differentiation induction action, it is useful as preventive and/or therapeutic agents for ischemic organ diseases (e.g., arteriosclerosis obliterans, Buerger disease, Raynaud disease, myocardial infarction, angina pectoris, diabetic neuropathy, spinal canal stenosis, cerebrovascular accidents, cerebral infarction, pulmonary hypertension, bone fracture, Alzheimer disease, etc.) and various cell and organ diseases. | 2008-12-04 |
20080299090 | Use Of Umbilical Cord Matrix Cells - The invention relates to the isolation and use of stem cells from amniote species (potentially any animal with an umbilical cord, including humans). More particularly the invention relates to obtaining stem cells that are at least multipotent and may be totipotent or nearly totipotent and are envisaged to have a variety of end uses. The cells of the present invention are immunosuppressive and may be used to inhibit the immune response in a subject. | 2008-12-04 |
20080299091 | Patient-specific stem cell lines derived from human parthenogenetic blastocysts - Methods are disclosed for generating HLA homozygous parthenogenetic human stem cell (hpSC-Hhom) lines from both HLA homozygous and HLA heterozygous donors. These hpSC-Hhom lines demonstrate typical human embryonic stem cell morphology, expressing appropriate stem cell markers and possessing high levels of alkaline phosphatase and telomerase activity. Additionally, injection of these cell lines into immunodeficient animals leads to teratoma formation. Furthermore, in the case of HLA heterozygous donors, the hpSC-Hhom lines inherit the haplotype from only one of the donor's parents. SNP data analysis suggests that hpSC-Hhom lines derived from HLA heterozygous oocyte donors are homozygous throughout the genome as assessed by single-nucleotide polymorphism (SNP) analysis. The protocol as disclosed minimizes the use of animal-derived components, which makes the stem cells more practical for clinical application. | 2008-12-04 |
20080299092 | Cosmetic preparation and method for preparing the same - The present invention relates to the use of dedifferentiated plant cells in cosmetic preparations for protecting of stem cells against intrinsic and extrinsic stress factors, in particular for promoting proliferation of stem cells and for protecting them against apoptosis. In particular, the invention relates to the use of dedifferentiated plant cells from fruits of | 2008-12-04 |
20080299093 | Premixed biological hydraulic cement paste composition and using the same - A premixed cement paste for use in medical or dental applications. The premixed cement paste remains fluid when stored in a hermetically sealed condition, but hydrates and hardens to set when placed in a physiological environment. The cement paste includes at least one calcium silicate compound and at least one substantially water-free liquid carrier mixed with the at least one calcium silicate compound; the substantially water-free liquid carrier avoids hydration of the mixture during storage, but undergoes exchange with aqueous physiological solutions so that the cement past hydrates and hardens to set when placed in a physiological environment. The paste may be placed in the physiological environment by injection, for example. The at least one calcium silicate compound may be, for example, calcium silicate, dicalcium silicate, tricalcium silicate, or mixtures thereof. The substantially water-free liquid may be, for example, ethylene glycol, polyethylene glycol, liquid glycerol, glycerin, ethyl alcohol, vegetable oil, animal oil, silicon oil, hydroxypropyl methylcellulose, or mixtures thereof. The substantially water-free liquid carrier preferably includes water in an amount less than about 20% by weight percent of the paste. The paste may include a secondary phase for enhanced properties, such as, for example, a fibrous or particulate material for enhanced mechanical properties, biodegradable or soluble materials that provide room for bone in-growth, bioactive materials such as antibiotics that elute into the physiological environment from the set cement, and radio-opaque materials that enhance X-ray imaging of the cement. | 2008-12-04 |
20080299094 | Methods and Kits for Predicting Liver Fibrosis Progression Rate in Chronic Hepatitis C Patients - Methods and kits for determining predisposition of an individual to develop fast progression rate of liver fibrosis are provided. Also provided are agents and pharmaceutical compositions useful in preventing fast progression of liver fibrosis and a method of identifying drug molecules which accelerate or induce liver fibrosis. | 2008-12-04 |
20080299095 | Nup98-Hox Fusions for Expansion of Hemopoietic Stem Cells - Nucleic acid constructs encoding homeobox-nucleoporin fusions are disclosed, compositions comprising same, and methods which provide enhanced expansion of stem cells. In particular, an isolated nucleic acid construct encoding a NUP98-HOX fusion is provided, which when introduced into hemopoietic stem cells provides enhanced expansion of these cells. Methods of expanding stem cells in vivo or ex vivo and methods of treatment using the stem cells are also described. | 2008-12-04 |
20080299096 | MODIFIED NUCLEOTIDE SEQUENCE ENCODING GLUCAGON-LIKE PEPTIDE-1 (GLP-1), NUCLEIC ACID CONSTRUCT COMPRISING SAME FOR PRODUCTION OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1), HUMAN CELLS COMPRISING SAID CONSTRUCT AND INSULIN-PRODUCING CONSTRUCTS, AND METHODS OF USE THEREOF - An isolated chimeric GLP-1 nucleic acid sequence encoding a human pro-insulin leader, a glucagon-like peptide-1 (GLP-1), and a furin cleavable site between the human pro-insulin leader sequence and the GLP-1 is provided. Also provided is an isolated modified chimeric GLP-1 nucleic acid sequence encoding a human pro-insulin leader, a glucagon-like peptide-1 (GLP-1), and a furin cleavable site between the human pro-insulin leader sequence and the GLP-1. Recombinant expression vectors comprising the chimeric GLP-1 nucleic acid sequences, which produce GLP-1 constitutively are provided, as are human cells transfected with such an expression vector in combination with an expression vector comprising a proinsulin nucleic acid sequence and an expression vector comprising a furin and a glucose-regulatable TGF-alpha promoter. Methods of producing human GLP-1 constitutively are provided as are method of producing GLP-1 and insulin or in a glucose-dependent manner using such transfected cells. Methods of treating a subject having Type II diabetes and methods of treating a subject prone to hyperglycemia or suffering from hyperglycemia are provided in which transfected cells produce human GLP-1 and insulin in a glucose-dependent manner. Also provided are methods of reducing weight in a subject by implanting into the subject transfected cells which produce human GLP-1 and insulin in a glucose-dependent manner. | 2008-12-04 |
20080299097 | ISOLATED POPULATION OF RAPIDLY PROLIFERATING MARROW STROMAL CELLS FOR ENHANCED IN VIVO ENGRAFTMENT - Multipotent stromal cells “MSCs” have been described as consisting of at least two populations of cells, rapidly self-renewing stem cells (RS-MSCs), and larger, slowly replicating cells (mMSCs). The present invention provides methods for enhancing engraftment of MSCs in vivo by administering an enriched fraction of RS-MSCs that express certain cell surface markers. | 2008-12-04 |
20080299098 | Broad-Spectrum Antibacterial and Antifungal Activity of Lactobacillus Johnsonii D115 - The present invention demonstrated the potential use of | 2008-12-04 |
20080299099 | Strain composition of the lactobacillus genus and the application of strain composition of the lactobacillus genus - A subject of the invention is a composition containing strains | 2008-12-04 |
20080299100 | Topical Co-Enzyme Q10 Formulations and Methods of Use - Topical formulations of CoQ10 reduce the rate of tumor growth in an animal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals. | 2008-12-04 |
20080299101 | Cancer Treatment Resistance and Agents Modulating Such Resistance - The present invention concerns a method for detecting in vitro resistance of cancer cells to a treatment by detecting in the cancer cells supernumerary nucleolar organizer regions (NOR), whereby identification of the presence of supernumerary NOR in the cancer cells is indicative of treatment resistance. The present invention also concerns a method for defining the capacity of a candidate agent to modulate NOR genes number of cancer cells by contacting the cancer cells with a candidate agent for a time sufficient to permit modulation of NOR genes number; and observing whether NOR genes number increases or decreases in said cancer cells. The present invention also provides a candidate agent that modulates NOR genes number of cancer cells obtained by the method of the invention and a composition for treating and/or preventing a cancer in a patient, comprising said candidate agent. Such a candidate agent decreases the NOR genes number in said cancer cells. | 2008-12-04 |
20080299102 | Novel BACE proteins, nucleic acid molecules therefor, novel crystal structure of novel BACE proteins, and methods for making and using - Disclosed and claimed are novel BACE proteins, crystal structures thereof, nucleic acid molecules therefor, and methods for making and using and uses of the same, especially for ascertaining inhibitors of BACE; and thus, disclosed and claimed too are inhibitors of BACE and methods of making and using the same. | 2008-12-04 |
20080299103 | Well Preserved Aqueous Organic Compositions - Well-preserved aqueous topical compositions that satisfy one or more widely recognized organic certification standards. The compositions comprise a preservative system comprising an in situ hypoiodite generator; and a plant extract blend; optionally, an essential oil blend. Such compositions do not require synthetic preservatives, especially parabens. Suitable aqueous compositions may contain an oil phase, such as oil-in-water or water-in-oil emulsions. | 2008-12-04 |
20080299104 | METHODS FOR DETECTING AGENTS INVOLVED IN NEURONAL APOPTOSIS AND COMPOSITIONS THEREOF - The invention provides methods of detecting and identifying agents which moduclate the expression or activity of synGAP, a brain-specific Ras/Rap GTPase activating protein. In vivo studies using knock-out and conditional knock-out transgenic animals show that the level of apoptosis in neurons correlates inversely with the level of synGAP protein, indicating that neuronal apoptosis is enhanced by reduction of synGAP. The invention also describes that synGAP is capable of modulating signal transduction pathways associated with the NMDA receptor and triggering apoptosis, including activation of Ras-GAP. Phosphorylation of synGAP by CaMKII increases its Ras GTPase-activating activity by about 70-95%. Moreover, when these and other phosphorylation sites in the synGAP carboxyl tail are mutated, stimulation of GAP activity after phosphorylation is reduced to about 21±5% as compared to about 70-95% for the wild type protein. Also, phosphosite-specific antibodies used to determine levels of synGAP phosphorylation are described herein. | 2008-12-04 |
20080299105 | Inhibition of Feline Calicivirus - We conducted feline calicivirus (FCV) inhibition experiment with two anti-viral aminohydrolases, asparaginase and glutaminase. We found that in the presence of 8 units and 4 units/ml of asparaginase, about 90% of FCV replication was inhibited. In contrast, glutaminase showed no significant inhibition effect on the virus replication. We have also shown that asparaginase did not inhibit the replication of adenovirus suggesting that the inhibition was specific. Our results implicated that asparaginase could be used as a candidate for anti-FCV drug development. | 2008-12-04 |
20080299106 | COMBINATIONS OF HUMAN PROTEINS TO ENHANCE IN VIVO VIABILITY OF STEM CELLS AND PROGENITOR CELLS - Embodiments of the present invention include the use of placental alkaline phosphatase and other members of the alkaline phosphatase family alone or in combination with human transferrin and, optionally, human α | 2008-12-04 |
20080299107 | COMBINATIONS OF HUMAN PROTEINS TO ENHANCE VIABILITY OF TRANSPLANTED STEM CELLS AND PROGENITOR CELLS - Embodiments of the present invention include the use of placental alkaline phosphatase alone or in combination with human transferrin and, optionally, human α | 2008-12-04 |
20080299108 | Peptides for Diagnostic and Therapeutic Methods for Celiac Sprue - Detection of toxic gluten oligopeptides refractory to digestion and antibodies and T cells responsive thereto can be used to diagnose Celiac Sprue. Analogs of such oligopeptides are useful in the inhibition of immune responses. | 2008-12-04 |
20080299109 | MECHANISM OF ASTRICYTE-NEURON SIGNALING - The present invention relates to a novel communication mechanism between astrocytes and neurons at a synapse. More specifically, the present invention relates to a signaling mechanism between astrocytes and neurons, by activating astrocytic G-protein coupled receptors, thereby activating glutamate receptors on a membrane of neighboring postsynaptic neurons, resulting in increasing the level of intracellular Ca | 2008-12-04 |
20080299110 | Methods and kits for diagnosing and treating acute joint injury - The present invention provides methods, reagents and kits for diagnosing and/or for the prognosis of non-autoimmune acute joint inflammation by detecting cytokine biomarkers in a sample obtained from an individual thought to be suffering from joint injury. The cytokine biomarkers used with the methods and kits of the present invention are IL-6, MIP-1β, MCP1 and IFNγ. | 2008-12-04 |
20080299111 | Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation - The invention provides compositions and methods for prevention and treatment of diseases associated with β-amyloid formation and/or aggregation. Such methods encompass the induction of an immune response against N-terminal truncated and/or post-translationally modified Aβ peptides. These peptides are further used in compositions and methods for the diagnosis of diseases associated with β-amyloid formation and/or aggregation. | 2008-12-04 |